nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—SLCO1A2—Chlorambucil—testicular cancer	0.351	0.439	CbGbCtD
Naloxone—CYP2C8—Ifosfamide—testicular cancer	0.0795	0.0994	CbGbCtD
Naloxone—SLCO1A2—Methotrexate—testicular cancer	0.0629	0.0786	CbGbCtD
Naloxone—ABCB1—Dactinomycin—testicular cancer	0.0456	0.057	CbGbCtD
Naloxone—CYP2C8—Etoposide—testicular cancer	0.038	0.0475	CbGbCtD
Naloxone—ALB—Methotrexate—testicular cancer	0.0325	0.0406	CbGbCtD
Naloxone—CYP3A4—Ifosfamide—testicular cancer	0.0322	0.0403	CbGbCtD
Naloxone—ABCB1—Vinblastine—testicular cancer	0.0285	0.0357	CbGbCtD
Naloxone—ABCB1—Cisplatin—testicular cancer	0.0262	0.0327	CbGbCtD
Naloxone—ABCB1—Etoposide—testicular cancer	0.0257	0.0322	CbGbCtD
Naloxone—ABCB1—Doxorubicin—testicular cancer	0.0175	0.0219	CbGbCtD
Naloxone—CYP3A4—Vinblastine—testicular cancer	0.0171	0.0214	CbGbCtD
Naloxone—ABCB1—Methotrexate—testicular cancer	0.017	0.0212	CbGbCtD
Naloxone—CYP3A4—Etoposide—testicular cancer	0.0154	0.0193	CbGbCtD
Naloxone—CYP3A4—Doxorubicin—testicular cancer	0.0105	0.0131	CbGbCtD
Naloxone—TLR4—female gonad—testicular cancer	0.00658	0.137	CbGeAlD
Naloxone—TLR4—testis—testicular cancer	0.00584	0.122	CbGeAlD
Naloxone—CREB1—embryo—testicular cancer	0.00525	0.11	CbGeAlD
Naloxone—TLR4—lymph node—testicular cancer	0.00423	0.0884	CbGeAlD
Naloxone—CREB1—gonad—testicular cancer	0.00357	0.0745	CbGeAlD
Naloxone—CREB1—female gonad—testicular cancer	0.0029	0.0605	CbGeAlD
Naloxone—CREB1—testis—testicular cancer	0.00257	0.0537	CbGeAlD
Naloxone—ESR1—embryo—testicular cancer	0.00207	0.0432	CbGeAlD
Naloxone—CREB1—lymph node—testicular cancer	0.00186	0.0389	CbGeAlD
Naloxone—Ventricular fibrillation—Ifosfamide—testicular cancer	0.00183	0.02	CcSEcCtD
Naloxone—Rhinorrhoea—Cisplatin—testicular cancer	0.00149	0.0163	CcSEcCtD
Naloxone—ESR1—gonad—testicular cancer	0.0014	0.0293	CbGeAlD
Naloxone—Ventricular tachycardia—Ifosfamide—testicular cancer	0.0014	0.0153	CcSEcCtD
Naloxone—OPRM1—testis—testicular cancer	0.00139	0.0289	CbGeAlD
Naloxone—CREB1—LKB1 signaling events—STK11—testicular cancer	0.00134	0.0219	CbGpPWpGaD
Naloxone—OPRD1—Peptide ligand-binding receptors—INSL3—testicular cancer	0.00128	0.0209	CbGpPWpGaD
Naloxone—Coma—Ifosfamide—testicular cancer	0.00128	0.014	CcSEcCtD
Naloxone—Pain—Carboplatin—testicular cancer	0.00125	0.0138	CcSEcCtD
Naloxone—Pulmonary oedema—Ifosfamide—testicular cancer	0.00125	0.0137	CcSEcCtD
Naloxone—SLCO1A2—testis—testicular cancer	0.00119	0.0249	CbGeAlD
Naloxone—ALB—testis—testicular cancer	0.00119	0.0248	CbGeAlD
Naloxone—Body temperature increased—Carboplatin—testicular cancer	0.00116	0.0127	CcSEcCtD
Naloxone—ESR1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00115	0.0187	CbGpPWpGaD
Naloxone—ESR1—female gonad—testicular cancer	0.00114	0.0238	CbGeAlD
Naloxone—CREB1—TCR Signaling Pathway—BCL10—testicular cancer	0.00114	0.0186	CbGpPWpGaD
Naloxone—OPRK1—Peptide ligand-binding receptors—INSL3—testicular cancer	0.00112	0.0183	CbGpPWpGaD
Naloxone—Depression—Vinblastine—testicular cancer	0.00108	0.0119	CcSEcCtD
Naloxone—CREB1—B Cell Receptor Signaling Pathway—BCL10—testicular cancer	0.00107	0.0175	CbGpPWpGaD
Naloxone—Hallucination—Chlorambucil—testicular cancer	0.00106	0.0116	CcSEcCtD
Naloxone—Encephalopathy—Methotrexate—testicular cancer	0.00103	0.0113	CcSEcCtD
Naloxone—ESR1—testis—testicular cancer	0.00101	0.0211	CbGeAlD
Naloxone—SLCO1A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000976	0.0159	CbGpPWpGaD
Naloxone—Cardiac arrest—Ifosfamide—testicular cancer	0.000966	0.0106	CcSEcCtD
Naloxone—OPRM1—Peptide ligand-binding receptors—INSL3—testicular cancer	0.000948	0.0155	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—PRDM14—testicular cancer	0.000885	0.0145	CbGpPWpGaD
Naloxone—ESR1—LKB1 signaling events—STK11—testicular cancer	0.000878	0.0143	CbGpPWpGaD
Naloxone—Tremor—Chlorambucil—testicular cancer	0.000866	0.0095	CcSEcCtD
Naloxone—ALB—lymph node—testicular cancer	0.00086	0.0179	CbGeAlD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000858	0.014	CbGpPWpGaD
Naloxone—Agitation—Chlorambucil—testicular cancer	0.00085	0.00932	CcSEcCtD
Naloxone—OPRM1—TCR Signaling Pathway—BCL10—testicular cancer	0.000842	0.0138	CbGpPWpGaD
Naloxone—Irritability—Cisplatin—testicular cancer	0.000836	0.00916	CcSEcCtD
Naloxone—CYP2C8—testis—testicular cancer	0.000833	0.0174	CbGeAlD
Naloxone—ABCB1—embryo—testicular cancer	0.000817	0.0171	CbGeAlD
Naloxone—Convulsion—Chlorambucil—testicular cancer	0.000801	0.00878	CcSEcCtD
Naloxone—Nasopharyngitis—Cisplatin—testicular cancer	0.000783	0.00859	CcSEcCtD
Naloxone—ABCB1—seminal vesicle—testicular cancer	0.000767	0.016	CbGeAlD
Naloxone—Flushing—Bleomycin—testicular cancer	0.000763	0.00837	CcSEcCtD
Naloxone—Cardiac arrest—Etoposide—testicular cancer	0.000763	0.00836	CcSEcCtD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000752	0.0123	CbGpPWpGaD
Naloxone—CREB1—Phospholipase C-mediated cascade—FGFR3—testicular cancer	0.000746	0.0122	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—BCL10—testicular cancer	0.000738	0.0121	CbGpPWpGaD
Naloxone—Chills—Bleomycin—testicular cancer	0.000738	0.00809	CcSEcCtD
Naloxone—Convulsion—Vinblastine—testicular cancer	0.000734	0.00805	CcSEcCtD
Naloxone—ESR1—lymph node—testicular cancer	0.000733	0.0153	CbGeAlD
Naloxone—Hypertension—Vinblastine—testicular cancer	0.000731	0.00802	CcSEcCtD
Naloxone—CREB1—Constitutive PI3K/AKT Signaling in Cancer—KITLG—testicular cancer	0.000713	0.0116	CbGpPWpGaD
Naloxone—Flushing—Dactinomycin—testicular cancer	0.000711	0.0078	CcSEcCtD
Naloxone—Hallucination—Ifosfamide—testicular cancer	0.000699	0.00767	CcSEcCtD
Naloxone—CREB1—Downstream signaling events of B Cell Receptor (BCR)—BCL10—testicular cancer	0.000695	0.0114	CbGpPWpGaD
Naloxone—Chills—Dactinomycin—testicular cancer	0.000688	0.00754	CcSEcCtD
Naloxone—CREB1—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.000663	0.0108	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—INSL3—testicular cancer	0.000653	0.0107	CbGpPWpGaD
Naloxone—Flushing—Ifosfamide—testicular cancer	0.000652	0.00715	CcSEcCtD
Naloxone—Cardiac disorder—Ifosfamide—testicular cancer	0.000652	0.00715	CcSEcCtD
Naloxone—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.000651	0.00714	CcSEcCtD
Naloxone—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000651	0.0106	CbGpPWpGaD
Naloxone—Pain—Chlorambucil—testicular cancer	0.000645	0.00708	CcSEcCtD
Naloxone—CREB1—PI-3K cascade—KITLG—testicular cancer	0.000642	0.0105	CbGpPWpGaD
Naloxone—Angiopathy—Ifosfamide—testicular cancer	0.000637	0.00699	CcSEcCtD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000636	0.0104	CbGpPWpGaD
Naloxone—Mediastinal disorder—Ifosfamide—testicular cancer	0.000633	0.00694	CcSEcCtD
Naloxone—Chills—Ifosfamide—testicular cancer	0.00063	0.00691	CcSEcCtD
Naloxone—CREB1—PI3K/AKT activation—KITLG—testicular cancer	0.000627	0.0102	CbGpPWpGaD
Naloxone—CREB1—GAB1 signalosome—KITLG—testicular cancer	0.000622	0.0102	CbGpPWpGaD
Naloxone—Paraesthesia—Vinblastine—testicular cancer	0.000621	0.00681	CcSEcCtD
Naloxone—Ventricular tachycardia—Epirubicin—testicular cancer	0.000619	0.00679	CcSEcCtD
Naloxone—Injection site reaction—Epirubicin—testicular cancer	0.000616	0.00675	CcSEcCtD
Naloxone—Mental disorder—Ifosfamide—testicular cancer	0.000615	0.00675	CcSEcCtD
Naloxone—CREB1—B Cell Activation—BCL10—testicular cancer	0.000614	0.01	CbGpPWpGaD
Naloxone—CREB1—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	0.000607	0.00992	CbGpPWpGaD
Naloxone—Coma—Methotrexate—testicular cancer	0.000605	0.00663	CcSEcCtD
Naloxone—Body temperature increased—Chlorambucil—testicular cancer	0.000596	0.00654	CcSEcCtD
Naloxone—Abdominal pain—Chlorambucil—testicular cancer	0.000596	0.00654	CcSEcCtD
Naloxone—Pain—Vinblastine—testicular cancer	0.000591	0.00648	CcSEcCtD
Naloxone—Pulmonary oedema—Methotrexate—testicular cancer	0.000589	0.00646	CcSEcCtD
Naloxone—CREB1—ATF-2 transcription factor network—MMP2—testicular cancer	0.000582	0.00952	CbGpPWpGaD
Naloxone—Ventricular tachycardia—Doxorubicin—testicular cancer	0.000573	0.00628	CcSEcCtD
Naloxone—OPRK1—GPCR ligand binding—INSL3—testicular cancer	0.000573	0.00936	CbGpPWpGaD
Naloxone—Injection site reaction—Doxorubicin—testicular cancer	0.00057	0.00625	CcSEcCtD
Naloxone—Coma—Epirubicin—testicular cancer	0.000566	0.00621	CcSEcCtD
Naloxone—Cardiac disorder—Cisplatin—testicular cancer	0.000562	0.00616	CcSEcCtD
Naloxone—Flushing—Cisplatin—testicular cancer	0.000562	0.00616	CcSEcCtD
Naloxone—Agitation—Ifosfamide—testicular cancer	0.000562	0.00616	CcSEcCtD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.00056	0.00915	CbGpPWpGaD
Naloxone—ABCB1—gonad—testicular cancer	0.000554	0.0116	CbGeAlD
Naloxone—Pulmonary oedema—Epirubicin—testicular cancer	0.000551	0.00605	CcSEcCtD
Naloxone—Abdominal pain—Vinblastine—testicular cancer	0.000547	0.00599	CcSEcCtD
Naloxone—Mediastinal disorder—Cisplatin—testicular cancer	0.000546	0.00599	CcSEcCtD
Naloxone—Asthenia—Chlorambucil—testicular cancer	0.000541	0.00594	CcSEcCtD
Naloxone—Convulsion—Ifosfamide—testicular cancer	0.00053	0.00581	CcSEcCtD
Naloxone—CREB1—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	0.00053	0.00865	CbGpPWpGaD
Naloxone—Hypertension—Ifosfamide—testicular cancer	0.000528	0.00579	CcSEcCtD
Naloxone—Paraesthesia—Bleomycin—testicular cancer	0.000524	0.00575	CcSEcCtD
Naloxone—Coma—Doxorubicin—testicular cancer	0.000524	0.00574	CcSEcCtD
Naloxone—Dyspnoea—Bleomycin—testicular cancer	0.000521	0.00571	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.000517	0.00567	CcSEcCtD
Naloxone—Diarrhoea—Chlorambucil—testicular cancer	0.000516	0.00566	CcSEcCtD
Naloxone—Flushing—Etoposide—testicular cancer	0.000515	0.00565	CcSEcCtD
Naloxone—Cardiac disorder—Etoposide—testicular cancer	0.000515	0.00565	CcSEcCtD
Naloxone—ESR1—Plasma membrane estrogen receptor signaling—MMP2—testicular cancer	0.00051	0.00834	CbGpPWpGaD
Naloxone—Pulmonary oedema—Doxorubicin—testicular cancer	0.00051	0.00559	CcSEcCtD
Naloxone—Angiopathy—Etoposide—testicular cancer	0.000503	0.00552	CcSEcCtD
Naloxone—ESR1—FOXM1 transcription factor network—MMP2—testicular cancer	0.000501	0.00818	CbGpPWpGaD
Naloxone—Mediastinal disorder—Etoposide—testicular cancer	0.0005	0.00548	CcSEcCtD
Naloxone—Pain—Bleomycin—testicular cancer	0.000499	0.00548	CcSEcCtD
Naloxone—Chills—Etoposide—testicular cancer	0.000498	0.00546	CcSEcCtD
Naloxone—Asthenia—Vinblastine—testicular cancer	0.000496	0.00544	CcSEcCtD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000496	0.0081	CbGpPWpGaD
Naloxone—Tremor—Cisplatin—testicular cancer	0.000494	0.00542	CcSEcCtD
Naloxone—CREB1—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000491	0.00802	CbGpPWpGaD
Naloxone—Nervous system disorder—Ifosfamide—testicular cancer	0.000489	0.00537	CcSEcCtD
Naloxone—CREB1—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	0.000486	0.00794	CbGpPWpGaD
Naloxone—Skin disorder—Ifosfamide—testicular cancer	0.000485	0.00532	CcSEcCtD
Naloxone—OPRM1—GPCR ligand binding—INSL3—testicular cancer	0.000484	0.00791	CbGpPWpGaD
Naloxone—Hyperhidrosis—Ifosfamide—testicular cancer	0.000482	0.00529	CcSEcCtD
Naloxone—Hot flush—Epirubicin—testicular cancer	0.000481	0.00527	CcSEcCtD
Naloxone—CREB1—Signaling by SCF-KIT—KITLG—testicular cancer	0.00048	0.00784	CbGpPWpGaD
Naloxone—Vomiting—Chlorambucil—testicular cancer	0.00048	0.00526	CcSEcCtD
Naloxone—CREB1—PI-3K cascade—FGFR3—testicular cancer	0.000477	0.00779	CbGpPWpGaD
Naloxone—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000477	0.00779	CbGpPWpGaD
Naloxone—Menopausal symptoms—Epirubicin—testicular cancer	0.000476	0.00523	CcSEcCtD
Naloxone—Diarrhoea—Vinblastine—testicular cancer	0.000473	0.00519	CcSEcCtD
Naloxone—Pain—Dactinomycin—testicular cancer	0.000466	0.00511	CcSEcCtD
Naloxone—CREB1—PI3K/AKT activation—FGFR3—testicular cancer	0.000466	0.00761	CbGpPWpGaD
Naloxone—CREB1—GAB1 signalosome—FGFR3—testicular cancer	0.000462	0.00755	CbGpPWpGaD
Naloxone—Body temperature increased—Bleomycin—testicular cancer	0.000462	0.00506	CcSEcCtD
Naloxone—CREB1—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.000459	0.0075	CbGpPWpGaD
Naloxone—Irritability—Methotrexate—testicular cancer	0.000459	0.00503	CcSEcCtD
Naloxone—Convulsion—Cisplatin—testicular cancer	0.000457	0.00501	CcSEcCtD
Naloxone—CREB1—Signaling by ERBB4—KITLG—testicular cancer	0.000452	0.00738	CbGpPWpGaD
Naloxone—CREB1—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	0.000451	0.00737	CbGpPWpGaD
Naloxone—ABCB1—female gonad—testicular cancer	0.000451	0.00941	CbGeAlD
Naloxone—Nausea—Chlorambucil—testicular cancer	0.000448	0.00492	CcSEcCtD
Naloxone—Paraesthesia—Ifosfamide—testicular cancer	0.000448	0.00491	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000446	0.00489	CcSEcCtD
Naloxone—TLR4—Innate Immune System—KITLG—testicular cancer	0.000445	0.00727	CbGpPWpGaD
Naloxone—Dyspnoea—Ifosfamide—testicular cancer	0.000445	0.00488	CcSEcCtD
Naloxone—Hot flush—Doxorubicin—testicular cancer	0.000445	0.00488	CcSEcCtD
Naloxone—Menopausal symptoms—Doxorubicin—testicular cancer	0.000441	0.00483	CcSEcCtD
Naloxone—Vomiting—Vinblastine—testicular cancer	0.00044	0.00482	CcSEcCtD
Naloxone—CREB1—PI-3K cascade—KIT—testicular cancer	0.000438	0.00716	CbGpPWpGaD
Naloxone—CREB1—Downstream signal transduction—KITLG—testicular cancer	0.000431	0.00705	CbGpPWpGaD
Naloxone—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000431	0.00473	CcSEcCtD
Naloxone—Body temperature increased—Dactinomycin—testicular cancer	0.000431	0.00472	CcSEcCtD
Naloxone—Abdominal pain—Dactinomycin—testicular cancer	0.000431	0.00472	CcSEcCtD
Naloxone—TLR4—Immune System—BCL10—testicular cancer	0.00043	0.00703	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR—KITLG—testicular cancer	0.000429	0.00701	CbGpPWpGaD
Naloxone—CREB1—PI3K/AKT activation—KIT—testicular cancer	0.000428	0.00698	CbGpPWpGaD
Naloxone—Cardiac arrest—Epirubicin—testicular cancer	0.000427	0.00469	CcSEcCtD
Naloxone—CREB1—Signaling by ERBB2—KITLG—testicular cancer	0.000427	0.00698	CbGpPWpGaD
Naloxone—Pain—Ifosfamide—testicular cancer	0.000427	0.00468	CcSEcCtD
Naloxone—CREB1—DAP12 signaling—KITLG—testicular cancer	0.000425	0.00695	CbGpPWpGaD
Naloxone—CREB1—GAB1 signalosome—KIT—testicular cancer	0.000424	0.00693	CbGpPWpGaD
Naloxone—Nervous system disorder—Cisplatin—testicular cancer	0.000422	0.00463	CcSEcCtD
Naloxone—Tachycardia—Cisplatin—testicular cancer	0.00042	0.00461	CcSEcCtD
Naloxone—CREB1—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.000419	0.00685	CbGpPWpGaD
Naloxone—Asthenia—Bleomycin—testicular cancer	0.000419	0.0046	CcSEcCtD
Naloxone—Convulsion—Etoposide—testicular cancer	0.000418	0.00459	CcSEcCtD
Naloxone—Skin disorder—Cisplatin—testicular cancer	0.000418	0.00458	CcSEcCtD
Naloxone—Hypertension—Etoposide—testicular cancer	0.000417	0.00457	CcSEcCtD
Naloxone—Hyperhidrosis—Cisplatin—testicular cancer	0.000416	0.00456	CcSEcCtD
Naloxone—CREB1—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	0.000414	0.00677	CbGpPWpGaD
Naloxone—Nausea—Vinblastine—testicular cancer	0.000411	0.0045	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000408	0.00448	CcSEcCtD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000407	0.00665	CbGpPWpGaD
Naloxone—Nasopharyngitis—Epirubicin—testicular cancer	0.000402	0.00441	CcSEcCtD
Naloxone—CREB1—Signaling by FGFR in disease—KITLG—testicular cancer	0.0004	0.00653	CbGpPWpGaD
Naloxone—CREB1—DAP12 interactions—KITLG—testicular cancer	0.0004	0.00653	CbGpPWpGaD
Naloxone—CREB1—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.0004	0.00653	CbGpPWpGaD
Naloxone—ABCB1—testis—testicular cancer	0.0004	0.00834	CbGeAlD
Naloxone—CREB1—Signaling by EGFR—KITLG—testicular cancer	0.000396	0.00648	CbGpPWpGaD
Naloxone—Cardiac arrest—Doxorubicin—testicular cancer	0.000396	0.00434	CcSEcCtD
Naloxone—Body temperature increased—Ifosfamide—testicular cancer	0.000395	0.00433	CcSEcCtD
Naloxone—Abdominal pain—Ifosfamide—testicular cancer	0.000395	0.00433	CcSEcCtD
Naloxone—CREB1—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000393	0.00642	CbGpPWpGaD
Naloxone—CREB1—Signaling by PDGF—KITLG—testicular cancer	0.000391	0.00639	CbGpPWpGaD
Naloxone—Asthenia—Dactinomycin—testicular cancer	0.000391	0.00429	CcSEcCtD
Naloxone—Paraesthesia—Cisplatin—testicular cancer	0.000386	0.00424	CcSEcCtD
Naloxone—Tachycardia—Etoposide—testicular cancer	0.000385	0.00422	CcSEcCtD
Naloxone—Dyspnoea—Cisplatin—testicular cancer	0.000384	0.00421	CcSEcCtD
Naloxone—Skin disorder—Etoposide—testicular cancer	0.000383	0.0042	CcSEcCtD
Naloxone—ESR1—ATF-2 transcription factor network—MMP2—testicular cancer	0.000381	0.00623	CbGpPWpGaD
Naloxone—Hyperhidrosis—Etoposide—testicular cancer	0.000381	0.00418	CcSEcCtD
Naloxone—Diarrhoea—Dactinomycin—testicular cancer	0.000373	0.00409	CcSEcCtD
Naloxone—Nasopharyngitis—Doxorubicin—testicular cancer	0.000372	0.00408	CcSEcCtD
Naloxone—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000371	0.00407	CcSEcCtD
Naloxone—Vomiting—Bleomycin—testicular cancer	0.000371	0.00407	CcSEcCtD
Naloxone—CREB1—B Cell Activation—KITLG—testicular cancer	0.00037	0.00605	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—INSL3—testicular cancer	0.000369	0.00603	CbGpPWpGaD
Naloxone—Depression—Methotrexate—testicular cancer	0.000369	0.00405	CcSEcCtD
Naloxone—Pain—Cisplatin—testicular cancer	0.000368	0.00404	CcSEcCtD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000367	0.00599	CbGpPWpGaD
Naloxone—Asthenia—Ifosfamide—testicular cancer	0.000358	0.00393	CcSEcCtD
Naloxone—CREB1—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000357	0.00583	CbGpPWpGaD
Naloxone—Sweating—Methotrexate—testicular cancer	0.000355	0.00389	CcSEcCtD
Naloxone—CREB1—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000354	0.00579	CbGpPWpGaD
Naloxone—Paraesthesia—Etoposide—testicular cancer	0.000354	0.00388	CcSEcCtD
Naloxone—Dyspnoea—Etoposide—testicular cancer	0.000351	0.00385	CcSEcCtD
Naloxone—Nausea—Bleomycin—testicular cancer	0.000347	0.0038	CcSEcCtD
Naloxone—Vomiting—Dactinomycin—testicular cancer	0.000346	0.0038	CcSEcCtD
Naloxone—Diarrhoea—Ifosfamide—testicular cancer	0.000341	0.00374	CcSEcCtD
Naloxone—CREB1—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000341	0.00557	CbGpPWpGaD
Naloxone—Gastrointestinal disorder—Etoposide—testicular cancer	0.00034	0.00373	CcSEcCtD
Naloxone—Body temperature increased—Cisplatin—testicular cancer	0.00034	0.00373	CcSEcCtD
Naloxone—Pain—Etoposide—testicular cancer	0.000337	0.0037	CcSEcCtD
Naloxone—CREB1—Signaling by GPCR—INSL3—testicular cancer	0.000336	0.0055	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB4—FGFR3—testicular cancer	0.000336	0.00549	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—INSL3—testicular cancer	0.000335	0.00548	CbGpPWpGaD
Naloxone—Sweating—Epirubicin—testicular cancer	0.000332	0.00364	CcSEcCtD
Naloxone—TLR4—Innate Immune System—FGFR3—testicular cancer	0.000331	0.00541	CbGpPWpGaD
Naloxone—CREB1—Signaling by SCF-KIT—KIT—testicular cancer	0.000327	0.00535	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—INSL3—testicular cancer	0.000324	0.00529	CbGpPWpGaD
Naloxone—Nausea—Dactinomycin—testicular cancer	0.000324	0.00355	CcSEcCtD
Naloxone—ESR1—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000321	0.00525	CbGpPWpGaD
Naloxone—CREB1—Downstream signal transduction—FGFR3—testicular cancer	0.000321	0.00524	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR—FGFR3—testicular cancer	0.000319	0.00521	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB2—FGFR3—testicular cancer	0.000318	0.00519	CbGpPWpGaD
Naloxone—Vomiting—Ifosfamide—testicular cancer	0.000317	0.00348	CcSEcCtD
Naloxone—CREB1—DAP12 signaling—FGFR3—testicular cancer	0.000316	0.00516	CbGpPWpGaD
Naloxone—CREB1—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000313	0.00512	CbGpPWpGaD
Naloxone—Abdominal pain—Etoposide—testicular cancer	0.000312	0.00342	CcSEcCtD
Naloxone—Body temperature increased—Etoposide—testicular cancer	0.000312	0.00342	CcSEcCtD
Naloxone—CREB1—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000311	0.00509	CbGpPWpGaD
Naloxone—Asthenia—Cisplatin—testicular cancer	0.000309	0.00339	CcSEcCtD
Naloxone—Cardiac disorder—Methotrexate—testicular cancer	0.000308	0.00338	CcSEcCtD
Naloxone—CREB1—Signaling by ERBB4—KIT—testicular cancer	0.000308	0.00504	CbGpPWpGaD
Naloxone—Sweating—Doxorubicin—testicular cancer	0.000307	0.00337	CcSEcCtD
Naloxone—TLR4—Innate Immune System—KIT—testicular cancer	0.000304	0.00496	CbGpPWpGaD
Naloxone—Angiopathy—Methotrexate—testicular cancer	0.000302	0.00331	CcSEcCtD
Naloxone—Mediastinal disorder—Methotrexate—testicular cancer	0.0003	0.00328	CcSEcCtD
Naloxone—Chills—Methotrexate—testicular cancer	0.000298	0.00327	CcSEcCtD
Naloxone—CREB1—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000297	0.00486	CbGpPWpGaD
Naloxone—CREB1—DAP12 interactions—FGFR3—testicular cancer	0.000297	0.00486	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000297	0.00486	CbGpPWpGaD
Naloxone—Nausea—Ifosfamide—testicular cancer	0.000296	0.00325	CcSEcCtD
Naloxone—ESR1—Signaling by ERBB4—KITLG—testicular cancer	0.000296	0.00483	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR—FGFR3—testicular cancer	0.000295	0.00481	CbGpPWpGaD
Naloxone—CREB1—Downstream signal transduction—KIT—testicular cancer	0.000294	0.00481	CbGpPWpGaD
Naloxone—Diarrhoea—Cisplatin—testicular cancer	0.000294	0.00323	CcSEcCtD
Naloxone—OPRK1—Signaling by GPCR—INSL3—testicular cancer	0.000294	0.0048	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR—KIT—testicular cancer	0.000293	0.00479	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000292	0.00477	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB2—KIT—testicular cancer	0.000292	0.00476	CbGpPWpGaD
Naloxone—Mental disorder—Methotrexate—testicular cancer	0.000291	0.00319	CcSEcCtD
Naloxone—CREB1—Signaling by PDGF—FGFR3—testicular cancer	0.000291	0.00475	CbGpPWpGaD
Naloxone—CREB1—DAP12 signaling—KIT—testicular cancer	0.00029	0.00474	CbGpPWpGaD
Naloxone—ABCB1—lymph node—testicular cancer	0.00029	0.00605	CbGeAlD
Naloxone—Cardiac disorder—Epirubicin—testicular cancer	0.000289	0.00317	CcSEcCtD
Naloxone—Flushing—Epirubicin—testicular cancer	0.000289	0.00317	CcSEcCtD
Naloxone—CREB1—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000286	0.00467	CbGpPWpGaD
Naloxone—Asthenia—Etoposide—testicular cancer	0.000283	0.0031	CcSEcCtD
Naloxone—Angiopathy—Epirubicin—testicular cancer	0.000282	0.00309	CcSEcCtD
Naloxone—Mediastinal disorder—Epirubicin—testicular cancer	0.00028	0.00307	CcSEcCtD
Naloxone—Chills—Epirubicin—testicular cancer	0.000279	0.00306	CcSEcCtD
Naloxone—CREB1—B Cell Activation—FGFR3—testicular cancer	0.000275	0.00449	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—INSL3—testicular cancer	0.000274	0.00447	CbGpPWpGaD
Naloxone—Vomiting—Cisplatin—testicular cancer	0.000274	0.003	CcSEcCtD
Naloxone—CREB1—Signaling by FGFR in disease—KIT—testicular cancer	0.000273	0.00446	CbGpPWpGaD
Naloxone—CREB1—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000273	0.00446	CbGpPWpGaD
Naloxone—CREB1—DAP12 interactions—KIT—testicular cancer	0.000273	0.00446	CbGpPWpGaD
Naloxone—Mental disorder—Epirubicin—testicular cancer	0.000272	0.00299	CcSEcCtD
Naloxone—CREB1—Signaling by NGF—KITLG—testicular cancer	0.000272	0.00445	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR—KIT—testicular cancer	0.00027	0.00442	CbGpPWpGaD
Naloxone—Diarrhoea—Etoposide—testicular cancer	0.00027	0.00296	CcSEcCtD
Naloxone—CREB1—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000268	0.00438	CbGpPWpGaD
Naloxone—Flushing—Doxorubicin—testicular cancer	0.000267	0.00293	CcSEcCtD
Naloxone—Cardiac disorder—Doxorubicin—testicular cancer	0.000267	0.00293	CcSEcCtD
Naloxone—CREB1—Signaling by PDGF—KIT—testicular cancer	0.000267	0.00436	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000266	0.00435	CbGpPWpGaD
Naloxone—Tension—Epirubicin—testicular cancer	0.000266	0.00291	CcSEcCtD
Naloxone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000264	0.00432	CbGpPWpGaD
Naloxone—CREB1—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000263	0.0043	CbGpPWpGaD
Naloxone—Nervousness—Epirubicin—testicular cancer	0.000263	0.00288	CcSEcCtD
Naloxone—Angiopathy—Doxorubicin—testicular cancer	0.000261	0.00286	CcSEcCtD
Naloxone—Mediastinal disorder—Doxorubicin—testicular cancer	0.000259	0.00284	CcSEcCtD
Naloxone—TLR4—Immune System—KITLG—testicular cancer	0.000259	0.00424	CbGpPWpGaD
Naloxone—Chills—Doxorubicin—testicular cancer	0.000258	0.00283	CcSEcCtD
Naloxone—CREB1—Innate Immune System—BCL10—testicular cancer	0.000258	0.00421	CbGpPWpGaD
Naloxone—Nausea—Cisplatin—testicular cancer	0.000256	0.0028	CcSEcCtD
Naloxone—CREB1—B Cell Activation—KIT—testicular cancer	0.000253	0.00413	CbGpPWpGaD
Naloxone—Mental disorder—Doxorubicin—testicular cancer	0.000252	0.00276	CcSEcCtD
Naloxone—Convulsion—Methotrexate—testicular cancer	0.000251	0.00275	CcSEcCtD
Naloxone—Vomiting—Etoposide—testicular cancer	0.000251	0.00275	CcSEcCtD
Naloxone—Agitation—Epirubicin—testicular cancer	0.000249	0.00273	CcSEcCtD
Naloxone—OPRM1—Signaling by GPCR—INSL3—testicular cancer	0.000249	0.00406	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—BCL10—testicular cancer	0.000247	0.00404	CbGpPWpGaD
Naloxone—Tension—Doxorubicin—testicular cancer	0.000246	0.0027	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000245	0.00268	CcSEcCtD
Naloxone—Nervousness—Doxorubicin—testicular cancer	0.000243	0.00267	CcSEcCtD
Naloxone—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000242	0.00396	CbGpPWpGaD
Naloxone—CYP2C8—Biological oxidations—HPGDS—testicular cancer	0.000242	0.00396	CbGpPWpGaD
Naloxone—CREB1—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000242	0.00395	CbGpPWpGaD
Naloxone—Convulsion—Epirubicin—testicular cancer	0.000235	0.00257	CcSEcCtD
Naloxone—Nausea—Etoposide—testicular cancer	0.000234	0.00257	CcSEcCtD
Naloxone—Hypertension—Epirubicin—testicular cancer	0.000234	0.00256	CcSEcCtD
Naloxone—Nervous system disorder—Methotrexate—testicular cancer	0.000232	0.00254	CcSEcCtD
Naloxone—Agitation—Doxorubicin—testicular cancer	0.00023	0.00252	CcSEcCtD
Naloxone—Skin disorder—Methotrexate—testicular cancer	0.000229	0.00252	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000229	0.00251	CcSEcCtD
Naloxone—Hyperhidrosis—Methotrexate—testicular cancer	0.000228	0.0025	CcSEcCtD
Naloxone—ESR1—Signaling by ERBB4—FGFR3—testicular cancer	0.00022	0.00359	CbGpPWpGaD
Naloxone—Convulsion—Doxorubicin—testicular cancer	0.000217	0.00238	CcSEcCtD
Naloxone—Nervous system disorder—Epirubicin—testicular cancer	0.000217	0.00238	CcSEcCtD
Naloxone—Hypertension—Doxorubicin—testicular cancer	0.000216	0.00237	CcSEcCtD
Naloxone—Tachycardia—Epirubicin—testicular cancer	0.000216	0.00237	CcSEcCtD
Naloxone—Skin disorder—Epirubicin—testicular cancer	0.000215	0.00235	CcSEcCtD
Naloxone—Hyperhidrosis—Epirubicin—testicular cancer	0.000214	0.00234	CcSEcCtD
Naloxone—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000212	0.00347	CbGpPWpGaD
Naloxone—Paraesthesia—Methotrexate—testicular cancer	0.000212	0.00233	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000212	0.00232	CcSEcCtD
Naloxone—Dyspnoea—Methotrexate—testicular cancer	0.000211	0.00231	CcSEcCtD
Naloxone—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000204	0.00224	CcSEcCtD
Naloxone—CREB1—Signaling by NGF—FGFR3—testicular cancer	0.000202	0.00331	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—KIT—testicular cancer	0.000202	0.0033	CbGpPWpGaD
Naloxone—Pain—Methotrexate—testicular cancer	0.000202	0.00221	CcSEcCtD
Naloxone—Nervous system disorder—Doxorubicin—testicular cancer	0.0002	0.0022	CcSEcCtD
Naloxone—Tachycardia—Doxorubicin—testicular cancer	0.0002	0.00219	CcSEcCtD
Naloxone—CREB1—Signaling Pathways—INSL3—testicular cancer	0.000199	0.00325	CbGpPWpGaD
Naloxone—Skin disorder—Doxorubicin—testicular cancer	0.000199	0.00218	CcSEcCtD
Naloxone—Paraesthesia—Epirubicin—testicular cancer	0.000198	0.00218	CcSEcCtD
Naloxone—OPRD1—Signaling Pathways—INSL3—testicular cancer	0.000198	0.00324	CbGpPWpGaD
Naloxone—Hyperhidrosis—Doxorubicin—testicular cancer	0.000198	0.00217	CcSEcCtD
Naloxone—Dyspnoea—Epirubicin—testicular cancer	0.000197	0.00216	CcSEcCtD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000194	0.00317	CbGpPWpGaD
Naloxone—TLR4—Immune System—FGFR3—testicular cancer	0.000193	0.00315	CbGpPWpGaD
Naloxone—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000191	0.00209	CcSEcCtD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000189	0.00309	CbGpPWpGaD
Naloxone—Pain—Epirubicin—testicular cancer	0.000189	0.00207	CcSEcCtD
Naloxone—Body temperature increased—Methotrexate—testicular cancer	0.000187	0.00205	CcSEcCtD
Naloxone—Abdominal pain—Methotrexate—testicular cancer	0.000187	0.00205	CcSEcCtD
Naloxone—CREB1—Signaling by NGF—KIT—testicular cancer	0.000186	0.00304	CbGpPWpGaD
Naloxone—Paraesthesia—Doxorubicin—testicular cancer	0.000184	0.00201	CcSEcCtD
Naloxone—ESR1—Gene Expression—DNMT3L—testicular cancer	0.000183	0.00299	CbGpPWpGaD
Naloxone—Dyspnoea—Doxorubicin—testicular cancer	0.000182	0.002	CcSEcCtD
Naloxone—TLR4—Immune System—KIT—testicular cancer	0.000177	0.00289	CbGpPWpGaD
Naloxone—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000177	0.00194	CcSEcCtD
Naloxone—Pain—Doxorubicin—testicular cancer	0.000175	0.00192	CcSEcCtD
Naloxone—Abdominal pain—Epirubicin—testicular cancer	0.000175	0.00192	CcSEcCtD
Naloxone—Body temperature increased—Epirubicin—testicular cancer	0.000175	0.00192	CcSEcCtD
Naloxone—OPRK1—Signaling Pathways—INSL3—testicular cancer	0.000174	0.00284	CbGpPWpGaD
Naloxone—Asthenia—Methotrexate—testicular cancer	0.000169	0.00186	CcSEcCtD
Naloxone—Abdominal pain—Doxorubicin—testicular cancer	0.000162	0.00177	CcSEcCtD
Naloxone—Body temperature increased—Doxorubicin—testicular cancer	0.000162	0.00177	CcSEcCtD
Naloxone—Diarrhoea—Methotrexate—testicular cancer	0.000162	0.00177	CcSEcCtD
Naloxone—Asthenia—Epirubicin—testicular cancer	0.000159	0.00174	CcSEcCtD
Naloxone—CREB1—Innate Immune System—KITLG—testicular cancer	0.000155	0.00254	CbGpPWpGaD
Naloxone—Diarrhoea—Epirubicin—testicular cancer	0.000151	0.00166	CcSEcCtD
Naloxone—Vomiting—Methotrexate—testicular cancer	0.00015	0.00165	CcSEcCtD
Naloxone—CREB1—Immune System—BCL10—testicular cancer	0.00015	0.00245	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—KITLG—testicular cancer	0.000149	0.00244	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—MMP2—testicular cancer	0.000149	0.00244	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—INSL3—testicular cancer	0.000147	0.0024	CbGpPWpGaD
Naloxone—Asthenia—Doxorubicin—testicular cancer	0.000147	0.00161	CcSEcCtD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000141	0.0023	CbGpPWpGaD
Naloxone—Vomiting—Epirubicin—testicular cancer	0.00014	0.00154	CcSEcCtD
Naloxone—Nausea—Methotrexate—testicular cancer	0.00014	0.00154	CcSEcCtD
Naloxone—Diarrhoea—Doxorubicin—testicular cancer	0.00014	0.00153	CcSEcCtD
Naloxone—Nausea—Epirubicin—testicular cancer	0.000131	0.00144	CcSEcCtD
Naloxone—ESR1—Signaling Pathways—INSL3—testicular cancer	0.00013	0.00213	CbGpPWpGaD
Naloxone—Vomiting—Doxorubicin—testicular cancer	0.00013	0.00143	CcSEcCtD
Naloxone—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.00013	0.00212	CbGpPWpGaD
Naloxone—Nausea—Doxorubicin—testicular cancer	0.000121	0.00133	CcSEcCtD
Naloxone—CREB1—Innate Immune System—FGFR3—testicular cancer	0.000115	0.00189	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—FGFR3—testicular cancer	0.000111	0.00181	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—MMP2—testicular cancer	0.000106	0.00174	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—KIT—testicular cancer	0.000106	0.00173	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—KIT—testicular cancer	0.000102	0.00166	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	9.3e-05	0.00152	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	9.25e-05	0.00151	CbGpPWpGaD
Naloxone—CREB1—Disease—H2AFZ—testicular cancer	9.08e-05	0.00148	CbGpPWpGaD
Naloxone—CREB1—Immune System—KITLG—testicular cancer	9.05e-05	0.00148	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—HPGDS—testicular cancer	8.43e-05	0.00138	CbGpPWpGaD
Naloxone—CREB1—Disease—KITLG—testicular cancer	8.36e-05	0.00137	CbGpPWpGaD
Naloxone—CREB1—Immune System—FGFR3—testicular cancer	6.73e-05	0.0011	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—H2AFZ—testicular cancer	6.41e-05	0.00105	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—H2AFZ—testicular cancer	6.36e-05	0.00104	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—H2AFZ—testicular cancer	6.34e-05	0.00104	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—STK11—testicular cancer	6.32e-05	0.00103	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—STK11—testicular cancer	6.3e-05	0.00103	CbGpPWpGaD
Naloxone—CREB1—Disease—FGFR3—testicular cancer	6.21e-05	0.00101	CbGpPWpGaD
Naloxone—CREB1—Immune System—KIT—testicular cancer	6.18e-05	0.00101	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—STK11—testicular cancer	6.12e-05	0.001	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KITLG—testicular cancer	5.85e-05	0.000956	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KITLG—testicular cancer	5.83e-05	0.000953	CbGpPWpGaD
Naloxone—CREB1—Disease—KIT—testicular cancer	5.7e-05	0.000932	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—H2AFZ—testicular cancer	5.56e-05	0.000908	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—STK11—testicular cancer	5.53e-05	0.000903	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KITLG—testicular cancer	5.11e-05	0.000836	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—H2AFZ—testicular cancer	4.7e-05	0.000768	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—STK11—testicular cancer	4.67e-05	0.000763	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—FGFR3—testicular cancer	4.35e-05	0.000711	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—FGFR3—testicular cancer	4.34e-05	0.000708	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KITLG—testicular cancer	4.32e-05	0.000706	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—H2AFZ—testicular cancer	4.17e-05	0.000681	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—STK11—testicular cancer	4.14e-05	0.000677	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—HPGDS—testicular cancer	4.14e-05	0.000677	CbGpPWpGaD
Naloxone—ALB—Metabolism—HPGDS—testicular cancer	4.12e-05	0.000673	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KIT—testicular cancer	3.99e-05	0.000652	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KIT—testicular cancer	3.98e-05	0.00065	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KITLG—testicular cancer	3.83e-05	0.000626	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—FGFR3—testicular cancer	3.8e-05	0.000621	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—HPGDS—testicular cancer	3.61e-05	0.000589	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KIT—testicular cancer	3.49e-05	0.00057	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FGFR3—testicular cancer	3.21e-05	0.000525	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—STK11—testicular cancer	3.01e-05	0.000492	CbGpPWpGaD
Naloxone—ALB—Metabolism—STK11—testicular cancer	2.99e-05	0.000489	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KIT—testicular cancer	2.95e-05	0.000482	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FGFR3—testicular cancer	2.85e-05	0.000465	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—STK11—testicular cancer	2.62e-05	0.000428	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KIT—testicular cancer	2.62e-05	0.000427	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HPGDS—testicular cancer	2.22e-05	0.000363	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—STK11—testicular cancer	1.61e-05	0.000264	CbGpPWpGaD
